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Recent cohort studies and meta-analyses suggest
that psoriasis is an independent risk factor for
stroke.1,2 Tumor necrosis factor-alfa (TNF-a) antag-
onists such as infliximab, adalimumab, and etaner-
cept are effective biological agents in the treatment
of moderate-to-severe psoriasis.3 The role of these
agents in preventing cardiovascular complications
and stroke in patients with psoriasis is less under-
stood. Here we describe the case of a young man
with severe psoriasis refractory to adalimumab,
presenting with thalamic stroke.CASE REPORT
The patient is a 40-year-old man with history of
plaque psoriasis and psoriatic arthritis for 12 years
refractory to conventional immunomodulatory ther-
apy, including methotrexate and etanercept.
Twenty months before the current presentation,
he was started on a 40-mg biweekly dose of
adalimumab and a 10-mg daily dose of prednisone.
Although the symptoms were better controlled with
adalimumab, the disease course was complicated
by 3 flares last year. The adalimumab dose was
increased to 40 mg weekly 6 months ago. In
addition, he was being considered for intravenous
infliximab treatment. Before treatment and during
relapse, involved body surface area was 20%.
Psoriasis Area and Severity Index was 18, and
during remission the Psoriasis Area and Severity
Index was 5. Cellulitis developed on his right elbow,
and adalimumab was stopped temporarily. Two
weeks later, he presented with a 3-day history of
progressive right-sided weakness, numbness, and
slurring of speech. The clinical presentation was
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and swelling of the metacarpophalangeal joints of
both hands.
On neurologic examination, the patient had com-
plete right hemiparesis, right-sided upper motor
neuron facial palsy, and right-sided hemianesthesia
with impaired touch and pain sensation. Vital signs,
complete blood counts, and basic metabolic panel
results were normal; his body mass index was 22.5. A
computed tomography scan of the head was not
revealing, and contrast-enhanced magnetic reso-
nance imaging showed an infarct in the left thalamus
and perithalamic white matter (Fig 2).
Because stroke is uncommon in this age group, he
was evaluated for thrombotic disorders, autoimmune
vasculitis, and structural heart disease. Coagulation
profile, including prothrombin time, partial throm-
boplastin time, thrombin time, and fibrinogen
levels, was normal. Factor V Leiden phenotype
was absent. The autoimmune markers antinuclear
antibody, ceantineutrophilic cytoplasmic antibody,
peantineutrophilic cytoplasmic antibody, anticyclic
citrullinated peptide, and lupus anticoagulant
were negative. Echocardiogram with bubble study
excluded thrombus and intracardiac shunts and
carotid Doppler excluded atheromas. Serum high-
sensitivity (hs)eC-reactive protein (CRP) level was
chronically elevated and did not show evidence
for acute exacerbation of systemic inflammation
(Fig 3).JAAD Case Reports 2015;1:324-6.
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Fig 3. Trend in hs-CRP level. Grey arrow points to the
initiation of adalimumab treatment. The black arrow
represents the point at which the dose was doubled.
Fig 2. Diffusion-weighted magnetic resonance imaging of
the brain shows lacunar infarct in the left thalamus (arrow).
Fig 1. Psoriatic skin lesions observed on patient’s right
lower limb.
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tered, as the patient was out of the 3- to 4.5-hour
window. Consequently, hewas conservatively treated
with aspirin, Plavix, and physical therapy. He
recovered rapidly and by day 8 of hospitalization,
both motor and sensory signs were resolved without
any residual impairment.
DISCUSSION
Thalamic stroke in this patient is consistent with
occlusion in the inferolateral artery affecting the
venteroposterolateral and venteroposteromedial
nuclei of the thalamus.4 The major risk factors for
thalamic stroke are hypertension, atherosclerosis,
embolism, and vasculitis. Based on the clinical
presentation, radiologic evidence, and chronic
elevation of hs-CRP, we believe that the cause of
stroke was likely thrombosis of the inferolateral
artery caused by progressive vascular inflammation.
From earlier studies, it is clear that psoriasis is a
systemic inflammation that could lead to increasedpredisposition for atherosclerosis and metabolic
syndrome.5 Additional risk factors for stroke
gradually developed in this patient during the
disease course. Hypertension was diagnosed 5 years
ago and diabetes mellitus 2 years ago. It is
important to note, however, that his hypertension
and diabetes (hemoglobin A1C, 7.2%) were well
controlled with medical therapy and lifestyle
modifications.
Adalimumab is a potent anti-inflammatory agent
that inhibits the inflammatory mediator TNF-a,
which is implicated in the pathogenesis of psoriasis.
Therefore, it is important to understand the role of
TNF-a inhibitors in preventing serious systemic
complications of psoriasis including myocardial
infarction and stroke. This subject has been
extensively reviewed by Nguyen et al.6 Overall,
studies found mixed results: certain studies found
that TNF-a inhibitor therapy lowered cardiovascular
complications and death, and others found no effect
compared with placebo or methotrexate.6 TNF
inhibitor therapy has also been found to reduce
inflammatory markers such as CRP, and increase
high-density lipoprotein. The probable mechanism
for reducing cardiovascular risk is improving
endothelial function and preventing plaque rupture.
In contrast, biological therapy with antieinterleukin-
2/23 agents (ustekinumab and briakinumab) has
resulted in increased cardiovascular adverse
events, although the study may not be powered
to make strong conclusions. In this patient,
treatment with adalimumab resulted in significant
reduction in the level of hs-CRP, a major biomarker
of systemic inflammation (Fig 3). However, such a
reduction was not enough to prevent stroke. It is
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reduction attained would still categorize him as
having moderate risk (10%e20%) for coronary
heart disease in the next 10 years based on
Centers for Disease Control and Prevention/
American Heart Association guidelines.7 There are
no specific guidelines for stroke prevention or a
target inflammatory biomarker level to reduce car-
diovascular risk factors in this patient population,
and it is not clear whether more aggressive treatment
would have altered the progression of psoriasis-
related complications in our patient. Along with
clinical remission, targeting hs-CRP levels based on
Centers for Disease Control and Prevention/
American Heart Association guidelines to reduce
cardiovascular risk factors would be an interesting
hypothesis to test. We anticipate that it would be an
important area of investigation for the future, and
this case report further emphasizes the need for such
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